The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome

Clinical Chemistry

Volumn 52, Issue 7, 2006, Pages 1223-1237

  Hortin, Glen L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN; PROTEOME;

CANCER DIAGNOSIS; CARDIOVASCULAR RISK; DISEASE MARKER; EARLY DIAGNOSIS; FRACTIONATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; KIDNEY FAILURE; LIVER INJURY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUTRITIONAL STATUS; PROTEIN ANALYSIS; PROTEOMICS; REVIEW;

BIOLOGICAL MARKERS; BLOOD PROTEINS; HUMANS; MOLECULAR WEIGHT; PEPTIDES; PLASMA; PROTEOME; REPRODUCIBILITY OF RESULTS; SERUM; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 33745442821     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.069252     Document Type: Review

References (126)

1. Tanaka K, Waki H, Ido Y, Akita S, Yoshida Y, Yoshida T. Protein and polymer analyses up to m/z 100,000 by laser ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1988;2:151-3.
2. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988;60:2299-301.
3. Reyzer ML, Caprioli RM. MALDI mass spectrometry for direct tissue analysis: a new tool for biomarker discovery. J Proteome Res 2005;4:1138-42.
4. Brown RS, Lennon JJ. Mass-resolution improvement by incorporation of pulsed ion extraction in a matrix-assisted laser desorption/ionization linear time-of-flight mass spectrometer. Anal Chem 1995;67:1998-2003.
5. Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 2005;51:1946-54.
6. S, Twerenbold D, Gerber D, Gritti D, Gonin Y, Netuschill A, Rossel F, et al. Single molecule detector for mass spectrometry with mass independent detection efficiency. Proteomics 2001;1:66-9.
7. Chait BT, Kent SBH. Weighing naked proteins: practical, high-accuracy mass measurement of peptide and proteins. Science 1992;257:1885-94.
8. Karas M, Gluckmann M, Schafer J. Ionization in matrix-assisted laser desorption/ionization: singly charged molecular ions are the lucky survivors. J Mass Spectrom 2000;35:1-12.
9. S. Sottani C, Fiorentino M, Minoia C. Matrix performance in matrix-assisted laser desorption/ionization for molecular weight determination in sialyl and non-sialyl oligosaccharide proteins. Rapid Commun Mass Spectrom 1997;11:907-13.
10. Belgacem O, Buchacher A, Pock K, Josic D, Sutton C, Rizzi A, et al. Molecular mass determination of plasma-derived glycoproteins by ultraviolet matrix-assisted laser desorption/ionization time-of-flight mass spectrometry with internal calibration. J Mass Spectrom 2002;37:1118-30.
11. Sekiya S, Wada Y, Tanaka K. Derivatization for stabilizing sialic acids in MALDI-MS. Anal Chem 2005;77:4962-8.
12. Wolfender JL, Chu F, Ball H, Wolfender F, Fainzilber M, Baldwin MA, et al. Identification of tyrosine sulfation in Conus pennaceus conotoxins a-PnlA and a-PnlB: further investigation of labile sulfo-and phosphopeptides by electrospray, matrix-assisted laser desorption/ionization (MALDI) and atmospheric pressure MALDI mass spectrometry. J. Mass Spectrom 1999;34:447-54.
13. Onnerfjord P, Heathfield TF, Heinegard D. Identification of tyrosine sulfation in extracellular leucine-rich repeat proteins using mass spectrometry. J Biol Chem 2004;279:26-33.
14. Krause E, Wenschuh H, Jungblut PR. The dominance of arginine-containing peptides in MALDI-derived tryptic mass fingerprints of proteins. Anal Chem 1999;71:4160-5.
15. Cockrill SL, Foster KL, Wildsmith J, Goodrich AR, Dapron JG, Hassell TC, et al. Efficient micro-recovery and guanidination of peptides directly from MALDI target spots. Biotechniques 2005;38:301-4.
16. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003;49:1041-4.
17. Kratzer R, Eckerskorn C, Karas M, Lottspeich F. Suppression effects in enzymatic peptide ladder sequencing using ultraviolet-matrix assisted laser desorption/ionization mass spectrometry. Electrophoresis 1998;19:1910-9.
18. Gilar M, Bouvier ESP, Compton BJ. Advances in sample preparation in electromigration, chromatographic, and mass spectrometric separation methods. J Chromatogr A 2001;909:111-35.
19. Kiernan UA, Black JA, Williams P, Nelson RW. High-throughput analysis of hemoglobin from neonates using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2002;48:947-9.
20. Jin Y, Manabe T. Direct targeting of human plasma for matrix-assisted laser desorption/ionization and analysis of plasma proteins by time-of-flight-mass spectrometry. Electrophoresis 2005;26:2823-34.
21. Hortin GL, Meilinger B, Drake SK. Size-selective extraction of peptides from urine for mass spectrometric analysis. Clin Chem 2004;50:1092-5.
22. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004;23:34-44.
23. Simpkins F, Czechowicz JA, Liotta L, Kohn EC. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics 2005;6:647-53.
24. Aivado M, Spentzos D, Alterovitz G, Out HH, Grall F, Giagounidis AA, et al. Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. Clin Chem Lab Med 2005;43:133-40.
25. Villaneuva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004;76:1560-70.
26. Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2005;51:973-80.
27. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61:6029-33.
28. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc Natl Acad Sci U S A 2005;102:10852-7.
29. Zhu Y, Valdes R Jr, Jortani SA. Application of bioaffinity mass spectrometry for analysis of ligands. Ther Drug Monit 2005;27:694-9.
30. Rossi L, Martin B, Hortin GL, White R, Foster M, Stroncek D, et al. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 2006;6:709-20.
31. Putnam FW. Alpha, beta, gamma, omega-the roster of the plasma proteins. In: Putnam FW, ed. The Plasma Proteins, 2nd ed., Vol. 1. New York: Academic Press, 1975:57-130.
32. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
33. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, et al. The human plasma proteome; a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3:311-26.
34. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5:3226-45.
35. Heinemann HO, Maack T, Sherman RI. Proteinuria. Am J Med 1974;56:71-81.
36. Brenner BM, Hostetter TH, Humes HD. Molecular basis of proteinuria of glomerular origin. N Engl J Med 1978;298:826-33.
37. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur J Clin Chem Clin Biochem 1996;34:517-20.
38. Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem 1999;274:22862-70.
39. 2+ concentrations. Biochemistry 2003;42:12335-48.
40. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005;51:1637-49.
41. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103:2096-104.
42. Lundblad RL. The Evolution from Protein Chemistry to Proteomics: Basic Science to Clinical Application. Boca Raton, FL: CRC Press, 2006:195-214.
43. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48.
44. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
45. Gaffney PJ. Fibrin degradation products: a review of structures found in vitro and in vivo. Ann N Y Acad Sci 2001;936:594-610.
46. Schultz DR, Arnold RI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, α1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum 1990;20:129-47.
47. Eriksen N, Benditt EP. Serum amyloid A (ApoSAA) and lipoproteins. ods Enzymol 1986;128:311-20.
48. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid α in renal cancer patients. Lab Invest 2004;84:845-56.
49. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 2005;51:695-707.
50. Moshkovski SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman El, Zgoda VG, et al. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005;5:3790-7.
51. Ferreira A, Urena P, Ang KS, Simon P, Morieux C, Souberbielle JC, et al. Relationship between serum β2-microglobulin, bone histology, and dialysis membranes in uraemic patients. Nephrol Dial Transplant 1995;10:1701-7.
52. Floege J, Bartsch A, Schulze M, Shaldon S, Koch KM, Smeby LC. Clearance and synthesis rates of β2-microglobulin in patients undergoing hemodialysis and in normal subjects. J Lab Clin Med 1991;118:153-65.
53. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-43.
54. 2-microglobulin with biological activity. Eur J Biochem 1987;163:21-8.
55. 2-microglobulin in renal failure patient urine and long-term dialysis patient blood. Clin Chim Acta 1995;236:135-44.
56. Kaplan B, Cohocaru M, Unsworth E, Knecht A, Martin BM. Search for peptidic "middle molecules" in uremic sera: isolation and chemical identification of fibrinogen fragments. J Chromatogr B 2003;796:141-53.
57. Copeland BE, Dyer PJ, Pesce AJ. Hemoglobin by first derivative spectrophotometry: extent of hemolysis in plasma and serum collected in vacuum container devices. Ann Clin Lab Sci 1989;19:383-8.
58. Woong-Shick A, Sung-Pil P, Su-Mi B, Joon-Mo L, Sung-Eun N, Gye-Hyun N, et al. Identification of hemoglobin-α and -β subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci 2005;96:197-201.
59. Koomen JM, Shin LN, Coombes KR, Li D, Xiao L, Fidler IJ, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005;11:1110-8.
60. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of disease. JAMA 2005;293:1653-62.
61. Bard E, Laibe S, Bettinger D, Riethmuller D, Biichle S, Seilles E, et al. New sensitive method for the measurement of lysozyme and lactoferrin for the assessment of innate mucosal immunity. Part 1: time-resolved immunofluorometric assay in serum and mucosal secretions. Clin Chem Lab Med 2003;41:127-33.
62. Sexton C, Duss D, Powell B, O'Connor M, Rainer R, Woodruff R, et al. Usefulness and limitations of serum and urine lysozyme levels in the classification of acute myeloid leukemia: an analysis of 208 cases. Leukemia Res 1996;20:467-72.
63. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:637-80.
64. Bradwell AR. Serum Free Light Chain Analysis, 2nd ed. Birmingham, UK: The Binding Site, 2004:13-47.
65. Nepomuceno AI, Mason CJ, Muddiman DC, Bergen HR 3rd, Zeldenrust SR. Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fourier-transform ion-cyciotron-resonance mass spectrometry. Clin Chem 2004;50:1535-43.
66. Schweigert FJ, Wirth K, Raila J. Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci 2004;2:5.
67. 6?. Bondarenko PV, Cockrill SL, Watkins LK, Cruzado ID, Macfarlane RD. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein. J Lipid Res 1999;40:543-55.
68. Penders J, Delanghe JR. α1-Microglobulin: clinical laboratory aspects and applications. Clin Chim Acta 2004;346:107-18.
69. Wild BJ, Green BN, Cooper EK, Lalloz MRA, Ertens S, Stephens AD, et al. Rapid identification of hemoglobin variants by electrospray ionization mass spectrometry. Blood Cells Mol Dis 2001;27:691-704.
70. Richter R, Schulz-Knappe P, Schrader M, Standker L, Jurgens M, Tammen H, et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B 1999;726:25-35.
71. Petricoin EF, Ardekani AM, Hitt VA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
72. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
73. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Araujo RP, Hood BL, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005;51:1933-45.
74. Villaneuva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exopeptidase activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84.
75. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006;116:26-30.
76. 7S. Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, Kikuchi S, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 2005;65:10613-22.
77. Hortin GL, Shen RF, Martin BM, Remaley AT. Diverse range of small peptides associated with high-density lipoprotein. Biochem Biophys Res Commun 2006;340:909-15.
78. Marshall J, Kupchak P, Zhu W, Yantha J, Vrees T, Furesz S, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003;2:361-72.
79. Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J, et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 2005;4:972-81.
80. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005;5:3262-77.
81. Traum AZ, Wells MP, Aivado M, Libermann TA, Ramoni MR, Schachter AD. SELDI-TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions. Proteomics 2006;6:1676-80.
82. Findeisen P, Sismanidis D, Riedl M, Costina V, Neumaier M. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2005;51:2409-11.
83. Karsan A, Eigl BJ, Slibotte S, Gelmon K, Switzer P, Hassell P, et al. Analytical and preanalytical biases in serum proteomic pattern analysis in breast cancer diagnosis. Clin Chem 2005;51:1525-8.
84. Drake SK, Bowen RAR, Remaley AT, Hortin GL. Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. Clin Chem 2004;50:2398-401.
85. Tammen H, Schulte I, Hess R, Menzel C, Kellmann M, Schulz-Knappe P, Prerequisites for petidomic analysis of blood samples: I. Evaluation of blood specimen qualities and determination of technical performance characteristics. Comb Chem High Throughput Screen 2005;8:725-33.
86. Randolph TW, Mitchell BL, McLerran DF, Lampe PD, Feng Z. Quantifying peptide signal in MALDI-TOF mass spectrometry data. Mol Cell Proteomics 2005;4:1990-9.
87. Tammen H, Hess R, Shulte I, Kellmann M, Appel A, Budde P, et al. Prerequisites for peptidomic analysis of blood samples: II. Analysis of human plasma after oral glucose challenge-a proof of concept. Comb Chem High Throughput Screen 2005;8:735-41.
88. Rossi L, Moharram R, Martin BM, White RL, Panelli MC. Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture. J Transi Med 2006;4:5.
89. Sokoll LJ, Wians FH Jr, Remaley AT. Rapid intraoperative immunoassay of parathyroid hormone and other hormones: a new paradigm for point-of-care testing. Clin Chem 2004;50:1126-35.
90. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21.
91. Zobel K, Koehler MF, Beresini MH, Caris LD, Combs D. Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo. Bioorg Med Chem Lett 2002;12:2883-6.
92. Vermeulen R, Lan Q, Zhang L, Gunn L, McCarthy D, Woodbury RL, et al. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proc Natl Acad Sci U S A 2005;102:17041-6.
93. Tammen H, Hess R, Uckert S, Becker AJ, Stief CG, Knappe PS, et al. detection of low-molecular-mass plasma peptides in the cavernous and systemic blood of healthy men during penile flaccidity and rigidity-an experimental approach using the novel differential peptide display technology. Urology 2002;59:784-9.
94. Semmes OJ, Feng Z, Adam B-L, Baenz LL, Bigbee WL, Campos D, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-12.
95. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? [Editorial]. Clin Chem 2005;51:3-5.
96. 9S. Plebani M. Proteomics: the next ,revolution in laboratory medicine? Clin Chim Acta 2005;357:113-22.
97. Haab BB, Geierstanger BH, Michailidis G, Vitzhum F, Forrester S, Okon R, et al. Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005;5:3278-91.
98. Rai AJ, Stemmer PM, Zhang Z, Adam BL, Morgan WT, Caffrey RE, et al. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005;5:3467-74.
99. Hu J, Coombes KR, Morris JS, Baggerly KA. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 2005;3:322-31.
100. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-78.
101. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 2005;11:963-5.
102. Silverman LM, Christenson RH. Amino acids and proteins. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry, 2nd ed. Philadelphia: WB Saunders, 1994:625-734.
103. Gotto AM Jr, Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. Methods Enzymol 1986;128:3-41.
104. Bhatnagar D, Durrington PN. Measurement and clinical significance of apolipoproteins A-I and B. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing, 2nd ed. Washington: AACC Press, 2000:287-310.
105. Bergen HR, Lacey JM, O'Brien JF, Naylor S. Online single-step analysis of blood proteins: the transferrin story. Anal Biochem 2001;296:122-9.
106. Labeur C, Rosseneu M. Immunological assays of apolipoproteins A-II, A-IV, C-I, C-II, and C-III in plasma: methods and applications. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing, 2nd ed. Washington: AACC Press, 2000:387-400.
107. Peters T Jr. Plasma proteins made by the liver. In: Glaumann H, Peters T Jr, Redman C, eds. Plasma Protein Secretion by the Liver. New York: Academic Press, 1983:1-5.
108. Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma β2-glycoprotein I. Proc Natl Acad Sci USA 1984;81:3640-4.
109. Preissner KT. Structure and biological role of vitronectin. Annu Rev Cell Biol 1991;7:275-310.
110. Ishioka N, Takahashi N, Putnam FW. Amino acid sequence of human plasma α1B-glycoprotein: homology to the immunoglobulin supergene family. Proc Nati Acad Sci U S A 1986;83:2363-7.
111. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HB Jr. Evaluation of apo A-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 1993;34:2207-15.
112. Ikewaki K, Zech LA, Brewer HB Jr, Rader DJ. ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apo A-II compared with the exogenous radiotracer method. J Lipid Res 1996;37:399-407.
113. Veldee MS. Nutrition. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry, 2nd ed. Philadelphia: WB Saunders, 1994:1236-74.
114. Nomura F, Tomonaga T, Sogawa K, Ohashi T, Nezu M, Sunaga M, et al. Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics 2004;4:1187-94.
115. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll U, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
116. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL, et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005;11:1073-85.
117. Cho WC, Yip TT, Yip C, Yip V, Thuiasiraman V, Ngan RK, et al. Identification of serum amyloid A as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10:43-52.
118. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005;51:2229-35.
119. Semmes OJ, Cazares LH, Ward MD, Qi L, Moody M, Maloney, et al. Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia 2005;19:1229-38.
120. Goncalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M, et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006;25:981-9.
121. Mitchell BL, Yasui Y, Lampe JW, Gafken PR, Lampe PD. Evaluation of matrix-assisted laser desorption/ionization-time of flight mass spectrometry proteomic profiling: identification of α2-HS glycoprotein B-chain as a biomarker of diet. Proteomics 2005;5:2238-46.
122. Kozak KR, Su F, Whitelegger JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589-96.
123. Orvisky E, Drake SK, Martin BM, Abdel-Hamid M, Ressom HW, Varghese RS, et al. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics 2006;6:in press. (Available online at DOI: 10.1002/pmic.200500443).
124. Pang RTK, Poon TCW, Chan KCA, Lee NLS, Chiu RWK, Tong YK et al. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem 2006;52:421-9.
125. Allard L, Lescuyer P, Burgess J, Leung K-Y, Ward M, Walter N, et al. Apo C-I, and apo C-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004;4:2242-51.
126. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chiang JTC, Wang HM, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 2005;51:2236-44.